HemOnc Today Current Issue

The following articles appeared in the print edition of HemOnc Today.

Table of Contents

• Right to Try: A ‘well-intentioned’ but ‘misguided’ law Jennifer Byrne
• Do examples of achieving remission with a drug obtained via Right to Try justify the law’s existence?
• Precision and uncertainty John Sweetenham, MD, FRCP, FACP
• Polypharmacy management among older adults with cancer requires multipronged approach Jai N. Patel, PharmD, BCOP, CPP
• Many US women eligible for breast-conserving therapy still opt for mastectomy Jennifer Byrne
• ASH president: ‘There is still so much to do’ Mark Leiser
• Enfortumab vedotin plus pembrolizumab induces durable responses in metastatic urothelial carcinoma John DeRosier
• Talazoparib active, safe among subset of men with metastatic prostate cancer John DeRosier
• Blood test could lead to earlier detection of gastrointestinal cancers Jennifer R. Southall
• Circulating tumor DNA predicts recurrence in early-stage triple-negative breast cancer Jennifer R. Southall
• Complete response, minimal residual disease negativity linked to lower relapse risk in relapsed/refractory AML John DeRosier
• Treatment at safety net cancer center may overcome racial disparities in DLBCL outcomes Alexandra (Sasha) Todak
• Adding gefitinib to chemotherapy improves PFS in EGFR-mutant lung cancer Jennifer R. Southall
• Gene therapy could be 'total game changer for many patients' with hemophilia A John DeRosier
• Adjuvant low-dose ipilimumab extends OS vs. high-dose interferon alfa-2b in metastatic melanoma Jennifer R. Southall
• FDA approves Tazverik for advanced epithelioid sarcoma
• FDA grants Orencia breakthrough therapy designation to prevent acute GVHD
• FDA grants breakthrough therapy designation to tucatinib for advanced breast cancer
• FDA grants priority review to Imfinzi for lung cancer subset
• Physicians join John Theurer Cancer Center medical staff
• Fox Chase Cancer Center announces faculty appointments